Category: FDA Drug Safety Oversight
-
Tavneos Warnings For VBDS Liver Side Effect Increased In April 2026
Tavneos Drug Label Change By Amgen Just 2 Days After Tavneos Drug Recall Statement By FDA (Posted by Tom Lamb at Drug Injury Watch) The Tavneos drug safety issue has an interesting new development. On April 29,…
-
Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026
Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon? (Posted by Tom Lamb at Drug Injury Watch) On March 31, 2026, the FDA issued a Tavneos liver…
-
Ozempic Tablets and Rybelsus Pancreatitis Side Effects Warnings 2026 Update
Acute Pancreatitis, Including Fatal Hemorrhagic And Necrotizing Pancreatitis – Death Cases (Posted by Tom Lamb at Drug Injury Watch) In October 2025, Rybelsus pancreatitis side effects warnings were added to the Rybelsus “drug label”, and in late…
-
Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs
Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION)…
-
Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma
While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years (Posted by Tom Lamb at Drug Injury Watch) Drug injury lawsuits that involve the contraceptive injection Depo-Provera being linked to…